Helping you make wiser investment decisions

Bristol Myers Squibb’s Opdivo-Yervoy combo helps mesothelioma patients live longer

April 20, 2020 Carly Helfand


Bristol-Myers Squibb’s Opdivo-Yervoy combo is awaiting some critical decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication, too.

The immuno-oncology duo topped chemo at extending the lives of phase 3 trial patients with previously untreated malignant pleural mesothelioma (MPM), the company said Monday.

The rare cancer, which forms in the lining of the lungs, is most commonly caused by asbestos exposure. It’s also a lethal one: On average, patients live for less than one year, and only 10% make it to the five-year mark post-diagnosis, BMS said.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year’s Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Bristol will present the full results at a future medical meeting, but between now and then, it’ll be discussing them with global regulators.

An indication in MPM would add another notch to the pairing’s belt. The regimen already bears go-aheads in melanoma, kidney cancer and liver cancer, among others.

Unlike in those hotly contested areas, though, no members of Opdivo’s PD-1/PD-L1 currently boast an MPM green light. Opdivo’s archrival, Keytruda, last year suffered a rare phase 3 miss in second-line patients, failing to improve survival outcomes against chemo, Leerink Partners analyst Daina Graybosch wrote in a Monday note to clients.

Still, an approval wouldn’t make much of a mark for Bristol sales-wise. About 3,300 new mesothelioma cases are reported in the U.S. each year, and that number “is declining, due to reduced population-wide exposure to asbestos,” Graybosch wrote.

RELATED: BMS nets another Opdivo lung cancer win—but it still has to beat Merck’s high bar

The real highlights for the checkpoint inhibitor combo could come later this year with nods in the ultra-lucrative non-small cell lung cancer field.

Bristol has watched from the sidelines for years as Merck’ has gobbled up market share with its Keytruda-chemo combo, but it’s finally up for some FDA decisions of its own: The agency is set to decide on Opdivo-Yervoy in previously treated patients by May 15 and on Opdivo-Yervoy-chemo in the same population by August 6.



Source link